2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3382 Impact of frontline induction treatment strategy on measurable residual disease clearance and post-transplant survival outcomes in pediatric and young adult acute myeloid leukemia

Lindsey A. Murphy, MD, MSCS, Xinyi Du2, Saro H Armenian, MD, MPH3, Sydney Ariagno, MD, MS4, Alysia Bosworth, BA5, Rohini Chakravarthy, MD, MPH6, Soohee Cho, MD, MSCS7, Erin Eileen Doherty, MD8, Caitlin W. Elgarten, MD, MSCE9, Vanessa A. Fabrizio, MD, MS10, Ellen Fraint, MD11, Zachary Graff, MD12, Nishi Arun Harwani, MBBS13, Jeffrey Huo, MD14, Victoria E. Lehrmann15, Lanie Lindenfeld16, Amanda Lipsitt, MD17, Katharine Morrison18, Megan M. Murphy, MD19, Yana Pikman, MD20, Troy C. Quigg, DO21, Akshay Sharma Jr, MBBS22, Pramika Sriram23, Heather J. Symons, MD24, Nicholas Tastet, BS25, Molly E. Thornock, BSN, RN, CPHON26, Dominique Tlomak27, Franziska Wachter, MD28, Sara Zarnegar-Lumley, MD29, F. Lennie Wong, PhD30, Amy Keating, MD31, Amanda C Winters, MD,PhD32
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 University of Colorado, Aurora, Colorado, United States
5 City of Hope, Duarte, California, United States
6 University of Chicago, Chicago, Illinois, United States
7 University of Utah, Salt Lake City, Utah, United States
8 Texas Children's Hospital, Houston, Texas, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 University of Colorado, Aurora, Colorado, United States
11 Nemours Children's Hospital, Wilmington, Delaware, United States
12 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
13 St. Judes Children's Research Hospital, Memphis, Tennessee, United States
14 Wake Forest University School of Medicine, Charlotte, North Carolina, United States
15 University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
16 City of Hope, Duarte, California, United States
17 Methodist Children’s Hospital, San Antonio, Texas, United States
18 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
19 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
20 Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
21 Corewell Health Helen DeVos Children’s Hospital, Grand Rapids, Michigan, United States
22 St. Judes Children's Research Hospital, Memphis, Tennessee, United States
23 University of Tennessee, Memphis, Tennessee, United States
24 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
25 Atrium Health Levine Children's Hospital, Charlotte, North Carolina, United States
26 City of Hope, Duarte, California, United States
27 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
28 Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
29 Lurie Children's Hospital, Chicago, Illinois, United States
30 City of Hope, Duarte, California, United States
31 Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
32 University of Colorado, Aurora, Colorado, United States

Background: Measurable residual disease (MRD), a key prognostic marker in pediatric acute myeloid leukemia (AML), increasingly guides risk stratification and treatment decisions. Frontline AML treatment has become increasingly diversified through alternative chemotherapy backbones and adoption of targeted therapies (TTx), with limited comparative evidence to guide regimen selection. Whether induction strategy influences early MRD clearance or long-term outcomes after hematopoietic cell transplantation (HCT) remains unclear. We evaluated the impact of frontline treatment strategy on MRD following induction cycles 1 and 2, as well as post-HCT outcomes in pediatric and young adult AML.  

Methods: This was a multicenter retrospective cohort study of patients ≤25 years old with AML diagnosed from 2012 to 2022 who underwent HCT in first complete remission (CR1). Patients with evaluable MRD after cycle 1 were included in this secondary analysis; those with persistent MRD or M2/M3 marrow and evaluable MRD after cycle 2 comprised the cycle 2 analysis. Frontline induction strategies were categorized as: DA (cytarabine [Ara-C] plus an anthracycline [daunorubicin, mitoxantrone, or idarubicin] ± TTx [e.g., gemtuzumab ozogamicin or FLT3 inhibitor]), ADE (Ara-C, daunorubicin, and etoposide ± TTx), FLA (fludarabine/Ara-C-based regimens), CPX-351 (liposomal Ara-C/daunorubicin), or other (including venetoclax-, clofarabine- and alternative Ara-C-based regimens). Analyses evaluated MRD-negative remission, defined as <0.01% by flow cytometry, following cycles 1 and 2. The combined effect of cycles 1 and 2 was categorized as continuation of the same approach, switch without intensification, or intensification, and evaluated for MRD-negative conversion post-cycle 2. Logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) for MRD clearance. Cox regression evaluated post-HCT overall survival (OS) and leukemia-free survival (LFS), while Fine-Gray analysis evaluated relapse. Multivariable models adjusted for significant covariables including age, sex, race/ethnicity, performance status, cytogenetic risk, HCT donor type, year of HCT, and extramedullary disease at diagnosis.

Results: The cohort included 443 patients who underwent HCT in CR1 at 15 institutions with evaluable MRD after cycle 1.  Median age was 11 years (range, 0-24), 53.5% were male, 52.4% were non-Hispanic White, and 71.6% had high-risk cytogenetics. Following cycle 1, 169 patients (38.1%) achieved MRD-negative remission. During cycle 1, 301 patients (68.0%) received ADE, 75 (16.9%) DA, 29 (6.6%) CPX-351, 22 (5.0%) other regimens, and 16 (3.6%) FLA. No significant differences were observed in MRD negativity across cycle 1 induction strategies.

Among 273 patients evaluable after cycle 2, 113 (41.4%) received DA, 80 (29.3%) ADE, 40 (14.7%) FLA, 19 (7%) CPX-351, and 21 (7.7%) other regimens. Following induction cycle 2, 142 patients (52%) achieved MRD-negative conversion. Compared with DA, ADE and CPX-351 were associated with lower odds of MRD negativity after cycle 2 (OR 0.54, 95% CI 0.30-0.97; p=0.038 and OR 0.18, 95% CI 0.06-0.57; p=0.004, respectively). MRD-negative conversion following cycle 2 did not differ between patients who continued the same approach and those who intensified or switched strategies (OR 0.96, 95% CI 0.57-1.61; p=0.871).

No significant differences in post-HCT OS or LFS were observed according to treatment strategy during either induction cycle. However, patients receiving ADE during cycle 1 had a higher hazard of relapse than those receiving DA (HR 1.76, 95% CI 1.04-2.98; p=0.036), whereas cycle 2 treatment strategy was not associated with relapse risk.

Conclusion: Among pediatric and young adult patients with AML who underwent HCT in CR1, MRD clearance did not differ across induction strategies after cycle 1, but ADE and CPX-351 were associated with lower MRD-negative conversion than DA after cycle 2. Switching or intensifying treatment after cycle 1 was not associated with greater MRD-negative conversion. Although induction strategy was not associated with post-HCT OS or LFS, ADE during cycle 1 was associated with higher post-HCT relapse than DA. Taken together, the lower MRD clearance in cycle 2 and higher relapse observed with ADE underscore induction strategy as a potentially important contributor to treatment response and long-term disease control, and support prospective studies to better define optimal induction approaches.
Lindsey A. Murphy, MD, MSCS: Jazz Pharmaceuticals - Speakers Bureau.